Oppenheimer Asset Management Inc. Has $681,000 Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Oppenheimer Asset Management Inc. boosted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 19.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,312 shares of the biotechnology company’s stock after buying an additional 708 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Sarepta Therapeutics were worth $681,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Innealta Capital LLC bought a new position in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $31,000. Mather Group LLC. bought a new position in Sarepta Therapeutics during the first quarter worth $28,000. Riggs Asset Managment Co. Inc. boosted its stake in Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 125 shares in the last quarter. New Covenant Trust Company N.A. acquired a new stake in Sarepta Therapeutics in the first quarter worth $32,000. Finally, Principal Securities Inc. bought a new stake in Sarepta Therapeutics in the fourth quarter valued at $26,000. Institutional investors own 86.68% of the company’s stock.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the completion of the transaction, the insider now directly owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the sale, the insider now directly owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The disclosure for this sale can be found here. Insiders sold a total of 52,801 shares of company stock worth $8,399,586 in the last quarter. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Trading Up 0.1 %

Shares of Sarepta Therapeutics stock opened at $127.21 on Friday. The firm has a market cap of $12.02 billion, a PE ratio of 1,156.45 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 1 year low of $55.25 and a 1 year high of $173.25. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The stock has a fifty day moving average price of $137.76 and a 200-day moving average price of $132.57.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The business had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.27) earnings per share. Equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 1.47 EPS for the current year.

Analyst Ratings Changes

SRPT has been the subject of several research reports. Leerink Partners raised their target price on Sarepta Therapeutics from $165.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, June 24th. Morgan Stanley restated an “overweight” rating and set a $165.00 price objective on shares of Sarepta Therapeutics in a report on Friday, June 21st. UBS Group increased their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday. Needham & Company LLC restated a “buy” rating and set a $235.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, June 27th. Finally, Citigroup dropped their price objective on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $187.39.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.